Imago BioSciences, a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, has announced a $40 million Series B financing led by Omega Funds, an international investment firm that creates and invests in life sciences companies.
Merck and NGM Biopharmaceuticals announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022.
US pharmaceutical company Pfizer has secured an exclusive option to acquire gene therapy firm Vivet Therapeutics in a deal that could be valued at around €560m ($635.8m).
A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML).
German biotech company Evotec has entered into a partnership with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics for the treatment of drug-resistant bacterial infections.
Ono Pharmaceutical and twoXAR have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
Imara, a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, announced the closing of an oversubscribed $63 million Series B cross-over financing.
Merck KGaA, Darmstadt, Germany, is collaborating with Iktos, a French start-up company specialized in artificial intelligence (AI) for new drug design, to further accelerate its drug discovery capabilities.
US-based Seres Therapeutics and AstraZeneca have entered into a three-year research collaboration, which will focus on further understanding the potential of microbiome therapeutics in supplementing immuno-oncology treatment.
InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.